Drug Search Results
More Filters [+]

PF-04878691

Alternative Names: pf-04878691, pf04878691, pf 04878691
Latest Update: 2009-12-01
Latest Update Note: Clinical Trial Update

Product Description

Pfizer was developing pf-04878691, an oral TLR7 Agonist for Hepatitis C Virus. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00810758)

Mechanisms of Action: TLR7 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PF-04878691

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Hepatitis C

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

B1201002

P1

Completed

Hepatitis C

2009-11-01

Recent News Events

Date

Type

Title